Skip to main content
Premium Trial:

Request an Annual Quote

Biametrics, MorphoSys to Expand High-Throughput Antibody Screening Collaboration

Premium

German technology firm Biametrics announced this week that it would expand its relationship with MorphoSys following a successful preliminary study that paired Biametrics' microarray technology with MorphoSys' therapeutic antibodies.

Florian Pröll, managing director at Tübingen-based Biametrics, said in a statement that the company "looks forward to expanding our collaboration in the field of biomolecular interaction analysis" with MorphoSys.

Biametrics and MorphoSys have been working together in the area of high-throughput antibody screening. According to Biametrics, in a pilot study, they used Biametrics' label-free B-screen microarray platform to characterize Fab fragment antigen interactions.

Biametrics recently launched B-screen as a research tool, and a handheld instrument called B-portable that relies on the same label-free technology is set for introduction later this year.

Markus Enzelberger, senior vice president and head of discovery alliances and technologies at MorphoSys, said in a statement that MorphoSys views B-screen as a "promising technology in the field of epitope mapping."

MorphoSys is based in Martinsried, Germany. The company maintains a therapeutic pipeline of more than 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.